Nikita Shah - 12 Nov 2025 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Reporting relationship: Executive Vice President
Issuer ticker: AMRX
Reported as of: 12 Nov 2025
Net transaction value: -$1,209,120
SEC form: 4
Accepted by SEC: 14 Nov 2025, 17:13:51 UTC
Prior SEC filing: 25 Aug 2025
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Denis Butkovic, Attorney-in-Fact

Key filing fact

Nikita Shah filed Form 4 for Amneal Pharmaceuticals, Inc. (AMRX) on 14 Nov 2025.

Key facts

This page summarizes Nikita Shah's Form 4 filing for Amneal Pharmaceuticals, Inc. (AMRX).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Nov 2025, 17:13.

Change

Previous filing in this sequence was filed on 25 Aug 2025.
Current net transaction value: -$1,209,120.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001738061 Primary reporting owner

Shah Nikita

Relationship: Executive Vice President
Address: C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BLVD., BRIDGEWATER
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Signature date: 14 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMRX transaction

Class A Common Stock

Options Exercise

Transaction value: $99,910
Shares: +36,331
Change %: +25%
Price: $2.75
Shares after: 182,734
Date: 12 Nov 2025
Ownership: Direct

AMRX transaction

Class A Common Stock

Options Exercise

Transaction value: $262,694
Shares: +95,525
Change %: +52%
Price: $2.75
Shares after: 278,259
Date: 12 Nov 2025
Ownership: Direct

AMRX transaction

Class A Common Stock

Sale

Transaction value: $1,571,724
Shares: -131,856
Change %: -47%
Price: $11.92
Shares after: 146,403
Date: 12 Nov 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMRX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -36,331
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Nov 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 36,331
Exercise price: $2.75
Footnotes: F2

AMRX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -95,525
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 12 Nov 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 95,525
Exercise price: $2.75
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $12.02 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F2

This option is fully vested.